Table 3 Summary of on-therapy treatment-emergent adverse events occurring in ≥10% of patients in either treatment arm (Safety population)
| Â | Asian patients, n (%) | Non-Asian patients, n (%) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|  | Pazopanib (n = 186) | Sunitinib (n = 177) | Pazopanib (n = 348) | Sunitinib (n = 355) | ||||||||
Preferred Term | Any grade | Grade 3 | Grade 4 | Any grade | Grade 3 | Grade 4 | Any grade | Grade 3 | Grade 4 | Any grade | Grade 3 | Grade 4 |
Neutropenia | 44 (24) | 11 (6) | 1 (< 1) | 77 (44) | 25 (14) | 5 (3) | 15 (4) | 4 (1) | 1 (< 1) | 68 (19) | 26 (7) | 1 (< 1) |
Neutrophil count decreased | 27 (15) | 2 (1) | 2 (1) | 47 (27) | 17 (10) | 0 | 1 (< 1) | 0 | 0 | 14 (4) | 7 (2) | 0 |
Neutropenia/neutrophil count decreaseda | 71 (38) | 13 (7) | 3 (2) | 124 (70) | 42 (24) | 5 (3) | 16 (5) | 4 | 1 | 82 (23) | 33 (9) | 1 |
Leukopenia | 40 (22) | 5 (3) | 0 | 59 (33) | 10 (6) | 0 | 11 (3) | 0 | 0 | 38 (11) | 4 (1) | 0 |
WBC count decreased | 24 (13) | 1 (< 1) | 0 | 52 (29) | 4 (2) | 0 | 4 (1) | 0 | 0 | 19 (5) | 4 (1) | 0 |
Leukopenia/ WBC count decreaseda | 64 (34) | 6 (3) | 0 | 111 (63) | 14 (8) | 0 | 15 (4) | 0 | 0 | 57 (16) | 8 | 0 |
Platelet count decreased | 30 (16) | 5 (3) | 0 | 62 (35) | 25 (14) | 5 (3) | 5 (1) | 0 | 0 | 38 (11) | 7 (2) | 1 (< 1) |
Thrombocytopenia | 31 (17) | 8 (4) | 2 (1) | 81 (46) | 39 (22) | 12 (7) | 24 (7) | 0 | 1 (< 1) | 100 (28) | 23 (6) | 7 (2) |
Thrombocytopenia/platelet count decreaseda | 61 (33) | 13 (7) | 2 (1) | 143 (81) | 64 (36) | 17 (10) | 29 (8) | 0 | 1 | 138 (39) | 30 | 8 |
Hemoglobin decreased | 21 (11) | 0 | 0 | 48 (27) | 8 (5) | 1 (< 1) | 12 (3) | 4 (1) | 0 | 21 (6) | 4 (1) | 0 |
Anemia | 13 (7) | 1 (< 1) | 3 (2) | 51 (29) | 10 (6) | 3 (2) | 24 (7) | 2 (< 1) | 3 (< 1) | 50 (14) | 11 (3) | 3 (< 1) |
Anemia/hemoglobin decreaseda | 34 (18) | 1 (< 1) | 3 (2) | 99 (56) | 18 (10) | 4 | 36 (10) | 6 | 3 | 71 (20) | 15 | 3 |